Andere Sprachen Janux Therapeutics, Inc.

Aktien

A3CR8F

US47103J1051

JANX

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:01 03.05.2024			% 5 Tage	% 1. Jan.
64.78 ^USD	+3.76%		+36.70%	+503.73%

16.04.	JANUX THERAPEUTICS, INC. : JonesTrading Institutional Services gibt eine Kauf-Bewertung ab	ZM
11.04.	Aktien New York: Dow erholt sich vor Start in die Berichtssaison	AW

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Sector Update: Health Care Stocks Slipping Late Afternoon	10.04.
Sector Update: Health Care	10.04.
Janux Therapeutics Said to be Considering Sale	10.04.
Janux Therapeutics Considering Options, Including Sale, Bloomberg Reports	10.04.
Janux Therapeutics Q4 Net Loss Narrows, Revenue Decreases	08.03.
Janux Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	08.03.
Janux Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	08.03.
Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights	08.03.
Janux Therapeutics Prices $296.5 Million Offering of Common Stock, Pre-Funded Warrants	29.02.
Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants	29.02.
Janux Therapeutics Announces Proposed Public Offering of Common Stock	27.02.
Sector Update: Health Care Stocks Ease Late Afternoon	27.02.
Sector Update: Health Care	27.02.
Top Midday Gainers	27.02.
Janux Therapeutics Shares Soar After Wedbush Boosts Price Target Following 'Positive' Data From Two Cancer Studies	27.02.
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Tuesday as Investors Await Key Data for Rate-Cut Hints	27.02.
Top Premarket Gainers	27.02.
Janux Therapeutics Discloses 'Positive' Data From Two Phase 1a Studies into Different Types of Cancers -- Shares Almost Double After Hours	26.02.
Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors	26.02.
Janux Therapeutics, Inc. Announces Positive Updated Clinical Data for Both of its Clinical Programs	26.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Janux Therapeutics, Inc.

Aktien

A3CR8F

US47103J1051

JANX

Andere Sprachen

Filter